Paradigm Biopharmaceuticals Director Increases Shareholding

Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.

Paradigm Biopharmaceuticals Ltd. has announced a change in the director’s interest, with Matthew James Fry acquiring an additional 350,000 fully paid ordinary shares through on-market trades. This acquisition raises Fry’s total holdings to 1,419,830 shares, reflecting his confidence in the company’s future prospects.

For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.